Nav: Home

Guidelines extended to improve the use of feedback from patients in clinical trials

February 06, 2018

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treatment on participating patients and their quality of life.

Protocols describe how a clinical trial will be conducted, including its objectives, design, methodology, statistical considerations and organisation, and ensures the safety of participating patients as well as the integrity of the data collected.

However, research* has found that sometimes there can be a lack of emphasis on patient-reported outcomes (PROs); feedback from patients about how the clinical trial has affected their overall health and quality of life.

Professor Melanie Calvert, Director of the Centre for Patient-Reported Outcomes Research (CPROR) at the University of Birmingham, said: "Patient-reported outcome data from clinical trials can provide valuable evidence to inform shared-decision making, pharmaceutical labelling claims, clinical guidelines, and health policy; however, clinical trial protocols often lack important information regarding the collection of quality of life and symptom data.

"Working in collaboration with international stakeholders we have developed consensus-based, PRO-specific protocol guidance to help ensure high-quality data to inform patient-centred care."

The recommended changes, published today in the Journal of the American Medical Association, follows research funded by charity Macmillan Cancer Support and was a collaboration by researchers across the globe including the universities of Birmingham, Toronto and Sydney.

Professor Jane Maher, Joint Chief Medical Officer at Macmillan Cancer Support, said: "As more new cancer treatments are tested as part of clinical trials, it is vital that we know about the impact they have on patients' lives. This will enable people to decide whether or not to have a particular treatment in the future.

"New cancer treatments can add months or even years to life, but they can also have side effects which can really have an impact on quality of life, in some cases long after treatment finishes. Such outcomes have often not been reported.

"These recommended changes to international guidelines will help ensure that people's experiences of new treatments are properly recorded and published, and I would urge researchers to adopt them."

Eleven extensions and five elaborations to the SPIRIT 2013 checklist are recommended for inclusion in clinical trial protocols where PROs are a primary or key secondary outcome. Extension items focused on PRO specific issues relating to the: trial rationale, objectives, eligibility criteria, concepts used to evaluate the intervention, time points for assessment, PRO instrument selection and measurement properties, data collection plan, translation to other languages, proxy completion, strategies to minimise missing data and whether PRO data will be monitored during the study to inform clinical care.

Professor Calvert adds: "While this guidance has been developed for trials where PROs are a primary or key secondary outcome, we are actively encouraging protocol writers to consider use of this guidance in all trials or clinical research studies where PROs are collected.

"The guidance does not aim to be prescriptive, but instead to encourage and facilitate careful planning of PRO components of trials, and thereby improve PRO trial design, which we hope will help staff and patients understand the rationale for PRO assessment, improve PRO data completeness and quality, facilitate high quality analysis and reporting, and ultimately improve the quality of the global PRO evidence base."

Daniel O'Connor, Expert Medical Adviser at the Medical and Healthcare products Regulatory Authority (MRHA), said: "We welcome initiatives to facilitate the standardisation of PRO data in clinical trials, which can contribute to a more robust patient focused drug development strategy."

Patient partner Gary Price said: "From my own personal experience of a serious illness and reporting my own outcomes, I was able to see how clinicians could use my PRO's proactively, helping them to make the right decisions thus speeding up my treatment and recovery.

"This research by the University of Birmingham has given me a good overview of how PRO's were being used and how the need for more guidance and consistency was paramount, in order to help all patients and clinicians contributing towards PRO trials and day to day usage, benefit from the results.

"Working on SPIRIT-PRO Extension, I can now see how this gives more focused guidance for protocol content within PRO's. Moving forward, it should help ensure high-quality data that can meaningfully inform patient-centred care."

Prof Calvert adds: "Improved reporting of PRO data from trials could not only help cancer patients make informed choices about their care, but also patients with a range of chronic disease."
*Davis et al (2017). 'Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.' BMJ

For further information or to arrange interviews, please contact:

For further information or interviews contact Emma McKinney, Press Office, University of Birmingham, on +44 (0)121 414 6681 or contact the Press Office out of hours on +44 (0)7789 921165. Patrick Pringle, Senior Media & PR Officer, Macmillan Cancer Support, on 0207 840 4891 (out of hours 07801 307068) or email:

Notes to Editors

The University of Birmingham is ranked amongst the world's top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 5,000 international students from over 150 countries.

The University of Birmingham's Centre for Patient-Reported Outcomes Research (CPROR) aims to optimize the use of PROs in clinical trials and routine care, to improve service delivery, enhance patient care and outcomes and ensure that the patient perspective is at the heart of health research and NHS decision-making. CPROR hosts a free PRO training resource for patients, clinicians and researchers, available at:

Calvert et al (2018). 'Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension'. the Journal of the American Medical Association. DOI: 10.1001/jama.2017.21903 For an embargoed copy of the paper, email

The authors of the paper were Melanie Calvert, Derek Kyte, Rebecca Mercieca-Bebber, Anita Slade, An-Wen Chan, Madeleine T King, and the SPIRIT-PRO Group.

The SPIRIT PRO Group consists of:
    1. University of Birmingham: Melanie Calvert, Derek Kyte, Anita Slade

    2. University of Sydney: Madeleine King, Rebecca Mercieca-Bebber,

    3. University of Toronto: An-Wen Chan

    4. University of Washington: Donald Patrick

    5. University of Oxford: Doug Altman

    6. University of North Carolina: Ethan Basch

    7. University of Leeds: Galina Velikova, Julia Brown

    8. University of Warwick: Heather Draper, Kirstie Haywood

    9. University of Bristol: Jane Blazeby, Joanna Coast

    10. Queen's University, Canada: Michael Brundage, Michael Palmer

    11. Medicines and Healthcare products Regulatory Agency: Daniel O'Connor, Lisa Campbell

    12. Patient Partners: Gary Price, Maria von Hildebrand

    13. Food and Drug Administration, USA: Laura Lee Johnson, Paul Kluetz

    14. Amanda Hunn, Health Research Authority

    15. Andrew Bottomley, European Organization for Research and Treatment of Cancer (EORTC), Belgium;

    16. Antoine Regnault, Modus Outcomes, France

    17. Carolyn Ells, Panel on Research Ethics (On behalf of the: Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada)

    18. Dennis Revicki, Evidera, USA

    19. Jane Scott, PhD, Janssen Global Services, Johnson and Johnson, UK;

    20. Josephine Norquist, Merck Sharp & Dohme Corporation, USA;

    21. Lori Frank, PhD, Patient-Centered Outcomes Research Institute (PCORI), USA;

    22. Richard Stephens, National Cancer Research Institute Consumer Forum, UK;

    23. Robert M Golub, JAMA, USA;

    24. Sandra Mitchell, National Cancer Institute, USA.

    25. Trish Groves, British Medical Journal (BMJ), UK.

The SPIRIT-PRO Extension was developed following the Enhancing QUAlity and Transparency Of health Research (EQUATOR) Network's methodological framework for guideline

The new international guidelines are known as the SPIRIT-PRO protocol checklist and has been developed by a team led by researchers from the University of Birmingham, and the University of Sydney in collaboration with international stakeholders including: clinical research personnel, PRO methodologists, health economists, psychometricians, patient advocates, funders, industry representatives, journal editors, policy makers, ethicists and researchers responsible for evidence synthesis.

This research was funded by Macmillan Cancer Support (grant number 5592105) and the University of Birmingham and was sponsored by the University of Birmingham. Prof King is supported by the Australian Government through Cancer Australia. Prof Blazeby is partially supported by the MRC ConDuCT-II Hub for Trials Methodology Research. Prof Calvert, Dr Kyte and Dr Slade are funded by the NIHR Birmingham Biomedical Research Centre and the NIHR Surgical Reconstruction and Microbiology Research Centre.

The National Institute for Health Research (NIHR): improving the health and wealth of the nation through research. Established by the Department of Health and Social Care, the NIHR:
  • funds high quality research to improve health

  • trains and supports health researchers

  • provides world-class research facilities

  • works with the life sciences industry and charities to benefit all

  • involves patients and the public at every step.

  • For further information, visit the NIHR website

There are 2.5 million people living with cancer in the UK. One in two people are likely to get cancer in their lifetimes. Cancer can affect everything, including a person's body, relationships and finances. Macmillan Cancer Support provides practical, emotional and personal support to people affected by cancer every year. The charity is there to support people during treatment, help with work and money worries, and listen when people need to talk about their feelings. Macmillan receives no government funding and relies on generous donations from the public. People up and down the country show their support for Macmillan - from hosting or attending a World's Biggest Coffee Morning to running a marathon or giving up alcohol - so the charity can help more and more people affected by cancer every year. Life with cancer is still your life and Macmillan is there to help you live it.

University of Birmingham

Related Clinical Trials Articles:

Giving children a voice in clinical trials
Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life -- even at the earliest stages of drug development -- making self-reported patient outcomes a potential new clinical trial endpoint.
Better health for women involved in clinical trials
Women who participate in obstetric and gynecology clinical trials experience improved health outcomes compared to those who are not involved in trials, according to research by Queen Mary University of London.
Final artificial pancreas clinical trials now open
Clinical trials are now enrolling to provide the final tests for a University of Virginia-developed artificial pancreas to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes.
Why the bar needs to be raised for human clinical trials
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
New drug formulary will help expedite use of agents in clinical trials
The National Cancer Institute (NCI) today launched a new drug formulary (the 'NCI Formulary') that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.
Review examines diversity in dermatology clinical trials
Racial and ethnic groups can be underrepresented in medical research.
Reshaping the future of global clinical trials practice
Researchers at the University of Liverpool have developed a new international guideline to help standardize how results from clinical trial studies are reported.
Fewer cardiovascular drugs being studied in clinical trials
The number of cardiovascular drugs in the research pipeline has declined across all phases of development in the last 20 years even as cardiovascular disease has become the No.
Sex hormones skew outcomes in clinical trials -- here's how
Clinical research often excludes females from their trials under the assumption that 'one size fits all,' that a painkiller or antidepressant will be equally effective in subjects of either sex, but a growing number of scientists are criticizing this approach.
Nearly half of pediatric clinical trials go unfinished or unpublished
Clinical trials in children commonly go either uncompleted or unpublished, finds a comprehensive study conducted by researchers at Boston Children's Hospital.

Related Clinical Trials Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...